The global cervical cancer diagnostic test market accounted for USD 7.45 Billion in 2020 and is expected to reach USD 15.45 Billion by 2028, expanding at a CAGR of 10.4% from 2021 to 2028.
The global cervical cancer diagnostic test market accounted for USD 7.45 Billion in 2020 and is expected to reach USD 15.45 Billion by 2028, expanding at a CAGR of 10.4% from 2021 to 2028.
Amongst the types of cancer identified as of now, cervical cancer is the one most prevalent amongst women. Research also states that 90% of the cases of cervical cancer could be attributed to HPV infection. The diagnosis happens through smear screening. The last few years have seen a substantial increase in the population of female smokers. Plus, the frequency of unsafe sex is increasing among teenagers. Therefore, the rate of cervical cancer is increasing in the young population.
The outbreak of COVID-19 has escalated the cervical cancer diagnostic tests, more so as the WHO has certified that those suffering from chronic diseases like cancer, and diabetes are more likely to contract Corona. These patients are trying to be doubly sure about the complexities, so that utmost care could be taken amidst the ongoing pandemic. The market for cervical cancer diagnostic tests is not expected to stand still by any means, looking at the situation on the whole.
The global cervical cancer diagnostic test market is significantly driven by the rise in the percentage of HPV in the female population. Lack of hygiene and non-awareness of cervical cancer in women is one of the significant factors to boost the need for cervical cancer diagnostic tests in women. According to CDC, more than seven million people acquire HPV in the U.S. Besides, changes in lifestyle, and availability of medical support are expected to propel the market growth. Genetic causes in women are also anticipated to contribute to the market growth in the coming years.
Report Attribute | Details |
---|---|
Base Year | 2022 |
Historic Years | 2018 - 2022 |
Forecast Years | 2023 - 2030 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2023 to 2030 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Based on the test, the global market of cervical cancer diagnostic test market is segmented as Pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC), and others. The Pap smear tests accounted for a significant share registering a high CAGR in the past few years. In addition, it is expected to continue dominating in the coming years. Factors such as growing awareness and low test prices are likely to influence commercial growth. The HPV testing segment is anticipated to have a second leading share attributed to rising in incidences of HPV infections in the population.
Based on end-user, the global market of cervical cancer diagnostics test market is trifurcated into hospitals, laboratories, and others. The hospital's segment was the leading segment in 2019. The segment is expected to continue its dominance during the forecast period.
North America held a significant share owing rise in awareness and presence of key players. Moreover, developed medical infrastructure offers lucrative opportunities for market development in the near future. The Asia Pacific is the second leading market for cervical cancer diagnostic tests owing to the large population with unmet medical needs. The rise in the geriatric population is one of the major reasons for growth within regional markets.
Some of the key players in the cervical caner diagnostic test market include Abbott Laboratories, Becton, Dickinson and Company, Femasys Inc., Hologic Inc., Oncohealth Corp, Quest Diagnostics Inc, QIAGEN and Zilico Ltd.
The Global Cervical Cancer Diagnostic Test Market is segmented into:
By Test:
By End-User:
By Region
FrequentlyAsked Questions
The global cervical cancer diagnostic test market was valued at USD 7.45 Billion in 2020.
The global cervical cancer diagnostic test market is expected to reach USD 15.45 Billion by 2028, expanding at a CAGR of 10.4% between 2021 to 2028.
Some of the key factors driving the global cervical cancer diagnostic test market growth comprise the lack of hygiene and non-awareness of cervical cancer in women is one of the significant factor to boost the need for cervical cancer diagnostic tests in women.
North America held a substantial share of the cervical cancer diagnostic test market in 2020 owing to the rise in awareness and the presence of top companies. China is world’s largest manufacturer of healthcare devices and advanced technology.
Some of the major companies operating in global cervical cancer diagnostic test market are Abbott Laboratories, Becton, Dickinson and Company, Femasys Inc., Hologic Inc., Oncohealth Corp, Quest Diagnostics Inc, QIAGEN and Zilico Ltd.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed